Skip to Content

Mallinckrodt PLC - Stock Quote MNKKQ

Rating as of

Morningstar's Mallinckrodt PLC Stock Analysis

There is no Morningtar’s Analysis data available.

Mallinckrodt PLC's Company Profile

Business Description

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which includes innovative specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of revenue from the United States.

College Business and Technology Park, Cruiserath
Dublin, 15, Ireland
T +353 16960000
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 2,800

Mallinckrodt PLC's Related Articles & News